Central nervous system involvement in anaplastic large cell lymphoma in childhood: Results from a multicentre European and Japanese study

• Published in: Pediatric blood & cancer 2013-10, Vol.60 (10), p.E118-E121
• Main Authors: Williams, Denise, Mori, Tetsuya, Reiter, Alfred, Woessman, Wilhelm, Rosolen, Angelo, Wrobel, Grazyna, Zsiros, Jozsef, Uyttebroeck, Anne, Marky, Ildiko, Le Deley, Marie-Cécile, Brugières, Laurence
• Format: Article
• Language: English
• Subjects: anaplastic large cell lymphoma; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Central Nervous System Neoplasms - drug therapy; Central Nervous System Neoplasms - mortality; Child; Child, Preschool; childhood; CNS disease; Cytarabine - administration & dosage; Disease-Free Survival; Europe; Follow-Up Studies; Hematology; Humans; Japan; lymphohistiocytic; Lymphoma, Large-Cell, Anaplastic - drug therapy; Lymphoma, Large-Cell, Anaplastic - mortality; Male; Methotrexate - administration & dosage; non-Hodgkin lymphoma; Oncology; Pediatrics; Pediatrik; Survival Rate
• ISSN: 1545-5009; 1545-5017; 1545-5017
• DOI: 10.1002/pbc.24591

In an international study of systemic childhood ALCL, 12/463 patients had CNS involvement, three of which had isolated CNS disease. Comparative analysis of CNS positive and negative patients showed no difference in ALK positivity, immunophenotype, presence of B symptoms or other sites of disease. The lymphohistiocytic variant was over represented in the CNS positive group (36% vs. 5%). With multi‐agent chemotherapy, including high dose methotrexate, Ara‐C and intrathecal treatment, the event free and overall survival of the CNS positive group at 5 years were 50% (95%CI, 25–75%) and 74% (45–91%), respectively with a median follow up of 4.1 years. Pediatr Blood Cancer 2013;60:E118–E121. © 2013 Wiley Periodicals, Inc.